自1974年研制成Oka株水痘减毒活疫苗以来,经在健康和免疫损害成人和儿童中试验,证实了其安全性和效力,在日本和韩国现已批准广泛应用,而仅在其他几个国家获准用于免疫损害患者。该疫苗将来可用于预防老年人带状疱疹、结合于多价疫苗中和在重组疫苗中作为表达外来基因的载体. The safety and efficacy of the Oka strain of varicella live vaccine developed since 1974 in adults and children under health and immunocompromised conditions have been approved for widespread use in Japan and South Korea, Countries are approved for immunocompromised patients. The vaccine may be used in the future to prevent shingles in the elderly, to be incorporated into multivalent vaccines, and to serve as a vector for expression of foreign genes in recombinant vaccines.